[{"orgOrder":0,"company":"Pharma Holdings","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LTX-109","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharma Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pharma Holdings \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"8","companyTruncated":"Pharma Holdings \/ CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"Pharma Holdings","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LTX-109","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharma Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pharma Holdings \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"8","companyTruncated":"Pharma Holdings \/ CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"Pharma Holdings","sponsor":"University Hospital of North Norway","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LTX-109","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Pharma Holdings","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pharma Holdings \/ University Hospital of North Norway","highestDevelopmentStatusID":"7","companyTruncated":"Pharma Holdings \/ University Hospital of North Norway"},{"orgOrder":0,"company":"Pharma Holdings","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LTX-109","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharma Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pharma Holdings \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"8","companyTruncated":"Pharma Holdings \/ CTC Clinical Trial Consultants"}]